LBA of lung cancer and breast cancer is about to be announced!2022 ESMO

*For medical professionals for reading reference

Tissue blood tidelle!

The most prestigious and influential oncology conference in Europe, the European Cancer Internal Science Society (ESMO) Annual Conference will arrive in September, this conference time is from September 9th to September 13th (Central EU Summer Time time To.

The editor of the "Medical Tumor Channel" compiled LBA (Late-Breaking-Abstract) in the field of lung cancer and breast cancer. Among them, 12 lung cancer fields and 7 breast cancer fields! (The following rankings are not distinguished, please forgive me if there are omissions, please leave a message to add)

Lung cancer

1. Specialty: Proffered Paper Session: Non-Metastative NSCLC and Other Thoracic Malignancies

Osimertinib as adjuvant therapy in Patients (PTS) With resect EGFR-Mutated (EGFRM) Stage IB -IIIA NON-Small Cell LUNGER (NSCLC): Updated Results FROM Adaula

Summary number: LBA47

Paris Time: September 11th 08: 30-08: 40

China Time: September 11 14: 30-14: 40

2. Specialty: Proffered Paper Session: NSCLC, Metastatic

Osimertinib Treatment Based on Plasma T790M Monitoring in Patients with EgFR-Mutant Non-Small Cell LUNG CANGER (NSCLC): EORTC LUNG CANCER Group 1613 Apple Phase II RANDOMED CLIND CLIND Clinical

Summary number: LBA51

Paris Time: September 11 14: 45-14: 55

China Time: September 11 20: 45-20: 55

3. Specialty: Proffered Paper Session: NSCLC, Metastatic

Elios: A Multicentre, Molecular Profiling Study of Patients (PTS) with Epidermal Growth Factor Receptor-Mutated (EGFRM) Advanced NSCLC Treated with First -Line

Summary number: LBA53

Paris Time: September 11 15: 05-15: 15

China Time: September 11 21: 05-21: 15

4. Specialty: Proffered Paper Session: Non-Metastatic NSCLC and Other Thoracic Malignannacies

Canopy-A: Phase III Study of Canakinumab (Can) As Adjuvant Therapy in Patients (PTS) with Completely Resected Non-Small Cell LUNG Cancer (NSCLC)

Summary number: LBA49

Paris Time: September 11th at 09: 25-09: 35

China Time: September 11 15: 25-15: 35

5. Specialty: Proffered Paper Session: NSCLC, Metastatic

TEPOTINIB + OSIMERTINIB for EGFRM NSCLC with MET AMPLIFICATION (METAMP) after Program on First-LINE (1L) Osimertinib: Initial Results from the Insight 2 Study

Summary number: LBA51

Paris Time: September 11 14: 55-15: 05

China Time: September 11 20: 55-21: 05

6. Specialty: Proffered Paper Session: Investigational Immunotherapy

A randomized, multicentric pHASE II Study of Preoperative Nivolumab Plus Relatlimab or Nivolumab in Patients with Resectable Non-Cell LUNG CANCER

Paris Time: September 9th 16: 00-16: 10

China Time: September 9 21: 00-21: 10

7. Specialty: Mini Oral Session: Non-Metastatic NSCLC and Other Thoracic MalignanCies

Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816

Summary number: LBA50

Paris Time: September 12 15: 25-15: 30

China Time: September 12 21: 25-21: 30

8. Specialty: Proffered Paper Session: NSCLC, Metastatic

Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non small cell lung cancer (NSCLC): the EMPOWER-Lung 1 trial

Summary number: LBA54

Paris Time: September 11 15: 35-15: 45

China Time: September 11 21: 35-21: 45

9. Specialty: Mini Oral Session: NSCLC, Metastatic

Medi5752 or PEMBROLIZUMAB (P) Plus Carboplatin/Pemetrexed (CP) in Treatment-Naïve (1L) Non-Small Cell LUNG Cancer (NSCLC): A PHASE 1B/2 TRIAL

Summary number: LBA56

Paris Time: September 11th 10: 20-10: 25

China Time: September 11 16: 20-16: 25

10. Specialty: mini oral session: nsclc, metastatic

Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

Summary number: LBA59

Paris Time: September 11: 05-11: 10

China Time: September 11 17: 05-17: 10

11. Specialty: mini oral session: nsclc, metastatic

Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small-cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: second interim analysis of phase 3 ORIENT-31 study

Summary number: LBA58

Paris Time: September 11th 10: 45-10: 50

China Time: September 11 16: 45-16: 5012, Special: MINI ORAL Session: NSCLC, Metastatic

Sintilimab Plus Anlotinib Versus Platinum-Based Chemotherapy as First-Line therapy in Metastatic NSCLC (Sunrise): An Open Label, Multi-CENTER, RANDOMIZED, PHASE 2 Study

Summary number: LBA57

Paris Time: September 11th 10: 45-10: 50

China Time: September 11 16: 45-16: 50

Breast cancer

1. Specialty: Proffered Paper Session: Breast Cancer, Early Stage

Nivolumab and iPilimumab in Early Stage Triple Negative Breast Cancer (TNBC) with Tumor-Infiltration Lymphocytes (TILS): First Results from the Belllini TRIALAL

Summary number: LBA13

Paris Time: September 10th 10: 25-10: 35

China Time: September 10th 16: 25-16: 35

2. Specialty: Proffered Paper Session: Breast Cancer, Metastatic

DALPICICLIB Plus Letrozole or Anastrozole As 1st-Line Treatment for HR+/HER2-Advanced Breast Cancer (DAWNA-2): A Phase 3 TRIAL

Summary number: LBA16

Paris Time: September 9th 16: 10-16: 20

China Time: September 9 20: 10-20: 20

3. Specialty: Proffered Paper Session: Breast Cancer, Metastatic

Primary endpoint results of SYNERGY, a randomized phase 2 trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC).

Summary number: LBA17

Paris Time: September 9th 16: 20-16: 30

China Time: September 9th 22: 20-22: 30

4. Specialty: mini oral session: Breast Cancer, metastatic

Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): a randomized, open-label, phase 2 trial

Summary number: LBA18

Paris Time: September 10th 14: 45-14: 50

China Time: September 10th 20: 45-20: 50

5. Specialty: mini oral session: Breast Cancer, metastatic

Pyrotinib or Placebo in Combination with Trastuzumab and DOCETAXEL for Her2-POSITIVE METASTASTASTAST CANCER (Phila): A Randomize 3 TRIAL

Summary number: LBA19

Paris Time: September 10th 14: 45-14: 50 China Time: September 10th 20: 45-20: 50

6. Specialty: mini oral session: Breast Cancer, metastatic

and cyclin-dependent Kinase 4/6 (CDK4/6i) Inhibitors

Summary number: LBA20

Paris Time: September 10th 15: 05-15: 10

China Time: September 10th 21: 05-21: 10

7. Specialty: Proffered Paper Session: Breast Cancer, Metastatic

Summary number: LBA76

Paris Time: September 9th 16: 20-16: 30

China Time: September 9th 22: 20-22: 30

The first release of this article: the medical world tumor channel

Author: oolong tea

Editor in charge: Sweet

- END -